ASTH — ASTRANA HEALTH INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying ASTH?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 2 tracked investors who changed their ASTH position last quarter, 1 bought and 1 sold (50% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).
- +1 tracked investor added or increased positions last quarter (Izzy Englander)
- +2 tracked investors reported holding ASTH at their latest filing
- +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
- −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.
About ASTRANA HEALTH INC (ASTH)
ASTRANA HEALTH INC (ASTH) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $35M. Across recent filings, tracked investors recorded 5 new positions, 4 increased, 9 reduced, and 4 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ASTH
How many top investors track ASTH
Only 2 tracked investors report this position.
ASTH Ownership Composition
How ASTRANA HEALTH INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant100.0%
Tracked investors currently reporting ASTH
2 tracked investors have since exited this position — listed separately below.
- Ken GriffinJun 30, 2026Citadel AdvisorsShares58.1KValue$2.7M% Portfolio0.00%
- Izzy EnglanderJun 30, 2026Millennium ManagementShares190.5KValue$8.8M% Portfolio0.00%
Previously held ASTH
These investors reported ASTH in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Steve Cohen | Point72 Asset Management | 24.8K | $1.4M | Sep 30, 2024 |
| Ray Dalio | Bridgewater Associates | 16.4K | $951.6K | Sep 30, 2024 |
Recent activity
- Reduced$992.7K(-68.50%)Nov 14, 2024
- Reduced$234.4K(-56.62%)Feb 14, 2025
- Sold$0(-100.00%)May 15, 2025
- $3.1MAug 14, 2025
- $334.4KFeb 17, 2026
- Increased$382.2K(15.65%)May 15, 2026
- Increased$8.8M(1122.11%)Aug 14, 2026
- Increased$34.6M(1191.46%)Nov 14, 2024
- Increased$12.1M(1142.99%)May 15, 2025
- Reduced$5.7M(-41.79%)Aug 14, 2025
- Sold$0(-100.00%)Nov 14, 2025
- Reduced$2.7M(-53.25%)Aug 14, 2026
- Reduced$1.7M(-4.13%)Feb 14, 2024
- Reduced$1.6M(-14.56%)May 14, 2024
- Reduced$1.4M(-9.56%)Aug 14, 2024
- Reduced$951.6K(-53.34%)Nov 13, 2024
- Sold$0(-100.00%)Feb 13, 2025
- Reduced$1.4M(-90.38%)Nov 14, 2024
- Sold$0(-100.00%)Feb 14, 2025
- New$1.5MNov 13, 2023
- New$10.4MSep 16, 2024
- New$1.9MAug 14, 2024
Frequently asked questions
- How many institutional investors hold ASTH?
- 2 tracked institutional investors disclosed a position in ASTH (ASTRANA HEALTH INC) in their most recent 13F filing.
- Who is the largest institutional holder of ASTH?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in ASTH, valued at $35M.
- Did institutional ownership of ASTH increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 4 increased, 9 reduced, and 4 fully exited ASTH.
- Where does this ASTH ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.